Valerie Vince’s Post

New treatments that are effective against resistant mutant AML is of high unmet need. Download this publication to learn how Crown Bioscience collaborated with Hanx Biopharmaceuticals and other cancer researchers for this study, investigating the efficacy of narazaciclib, a novel multi-kinase inhibitor, and how it targets and inhibits key kinases involved in AML models. You can also learn more about which Crown Bioscience AML preclinical models were used. #OncologyResearch #DrugDevelopment #AcuteMyeloidLeukemia

We're thrilled to announce the publication of groundbreaking research on narazaciclib and its anti-AML activity in preclinical models with specific AML mutations of clinical significance. This collaboration between Hanx Biopharmaceuticals, Crown Bioscience, and other cancer researchers has revealed promising results in targeting and inhibiting key kinases involved in AML. Dive deeper into our findings and discover how our collaborative efforts are contributing to treatments for AML. ➡️ https://bit.ly/3UrLjH7 #OncologyResearch #DrugDevelopment #AcuteMyeloidLeukemia

🌟𝗡𝗲𝘄 𝗕𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗶𝗻 𝗦𝘁𝗼𝗰𝗸: 𝗧𝗲𝗰𝗹𝗶𝘀𝘁𝗮𝗺𝗮𝗯🚀🧬 Teclistamab from the original drug Tecvayli®, a new #bispecific antibody, is making strides in the fight against multiple myeloma. 💪 Utilizing advanced biotechnology, Teclistamab simultaneously targets T cells and cancer cells, recruiting T cells to destroy the malignant cells. This innovative approach offers new hope for patients battling this incurable blood cancer. 🎗️ Visit our online shop to access Teclistamab and other licensed molecules in smaller units. 🛒 We also offer historical batches of original and biosimilar drugs for your research and early drug development projects. 🔬 #antibody #bloodcancer #biotechnology #cancerresearch #immunotherapy #globalreach #research #drugdevelopment #accessibleresearch

Read our publication of groundbreaking research on narazaciclib and its anti-AML activity in preclinical models, with specific AML mutations of clinical significance. This collaboration between Hanx Biopharmaceuticals, Crown Bioscience, and other cancer researchers has revealed promising results in targeting and inhibiting key kinases involved in AML. Dive deeper into our findings and discover how our collaborative efforts are contributing to treatments for AML. ➡️ https://hubs.la/Q02JRWm80 #OncologyResearch #DrugDevelopment #AcuteMyeloidLeukemia

Innovative Combination of Chemical Drug and Near-infrared Light Successfully Targeted Cancerous Cells: A novel combination drug designed to combat cancer by manipulating calcium ions inducing a lethal "calcium storm" within tumor cells. The scientists strategically targeted two distinct calcium channels within the cell: one residing in the outer membrane and the other located in the endoplasmic reticulum—an organelle responsible for storing calcium ions. To generate the necessary ROS for opening the outer membrane calcium channel, the research team employed a dye known as indocyanine green. This bioactive agent can be activated through exposure to near-infrared light, a process that not only stimulates the production of ROS but also raises the local temperature. #cancer #oncology #prostatecancer #skincanc #drugdiscovery #drugdelivery #formulation #drugdevelopment #pharmaceuticals #medicalsciences #pharmaceutics #medicine #research Ghaleb Husseini

We are excited to share that RECEPTOR.AI is entering in partnership with Moexa Pharmaceuticals, Inc. to drive the discovery and development of novel small molecule therapeutics targeting protein-protein interactions (PPIs) for cancer and fibrosis treatment. This collaboration will leverage our Induced Proximity Platform, to develop PPIs modulating compounds, advancing the frontiers of AI-powered drug discovery. Together with Moexa's deep expertise in cancer and fibrosis biology, we are poised to accelerate the creation of transformative therapies. For more details, visit our website and read the full press release: https://lnkd.in/ejG7xSt7 Learn more about our Induced Proximity Platform: https://lnkd.in/eNfRMx_P #Partnership #AI #DrugDiscovery #Cancer #Fibrosis #Biotechnology #Innovation

#ACROHighlights [Featured Product] 🔑 Unleash the Potential of MMPs in Cancer Therapeutics 🔬 Unlock the secrets of the tumor microenvironment with our recombinant MMP proteins. Matrix Metalloproteinases (MMPs) are key players in remodeling the TME, driving tumor growth, invasion, and metastasis. Explore our premium MMP products (MMP-1, MMP-2, MMP-3, and more) to uncover new cancer research and therapeutic development frontiers. Leverage the versatile capabilities of these enzymes to propel your pharmaceutical R&D to new heights. 💊💪 🔗https://lnkd.in/gm7TPZbd #TumorMicroenvironment #MatrixMetalloproteinases #CancerResearch #Biotechnology #MMPs

PCA Platform for Drug Discovery toward Undruggable Protein Targets. Protein Conformational Array (PCA) is a well-established ELISA-based technology to analyze protein conformational change systematically. It can be used to identify molecules disrupting ANY protein targets. Our proof-of-concept study demonstrated that small molecules identified from SHP2 or KRAS conformation (Higher Order Structure) disruption resulted in the degradation of the targets in multiple cancer cell lines. PCA could be a promising new approach for drug discovery toward the undruggable targets which constitute 85% of the possible drug targets in the human proteome.

This week, our CSO, Nick Stub Laursen, will be attending the 16th International Conference on Complement Therapeutics in Loutraki, Ancient Corinth, Greece.    Nick will be delivering a poster presentation on new data from Commit Biologics innovative BiCE platform which will show that Commit’s second generation #BiCE™ molecules induce superior complement-mediated cell killing compared to other technologies.   With a novel mechanism of action, Commit’s technology has the potential to be developed into best-in-class therapeutics for the treatment of cancer and autoimmune diseases.   To read more on the presentation, read the press release in the comments below!   #ComplementSystem #ImmuneSystem #Antibodies

An other molecule that has relatedness to breast cancer C22H34N2O4 According to San Diego University website the molecule Target Sodium-dependent dopamine transporter(Homo sapiens (Human)) Target Sodium-dependent noradrenaline transporter(Homo sapiens (Human)) Target Sodium-dependent serotonin transporter(Homo sapiens (Human)) From wiki :The serotonin transporter is also present in platelets; there, serotonin functions as a vasoconstrictive substance. It also serves as a signalling molecule to induce platelet aggregation. Special thanks to The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields. https://lnkd.in/eq2Ueqpf